FLC is a rare liver cancer with unique genetic traits, often misdiagnosed until advanced. New research and a clinical trial ...

Salk scientists have found that eliminating the bile acid-producing protein BAAT and supplementing with the bile acid UDCA ...

Long classified as a subset of common liver cancer, FLC should be considered its own unique disease. Now researchers are testing a combination drug therapy that targets FLC tumors.

New insights into fibrolamellar hepatocellular carcinoma could lead to new drugs and significantly improved health outcomes.

Immunotherapy is a modern approach to cancer treatment that uses a patient's own immune system to help fight tumors. It has ...

撰文 | 唐东豪   责编 | 周叶斌在儿童肿瘤中，原发性肝癌（PLC）相对罕见，仅占所有儿童癌症的0.5%至1.5%。主要包括肝母细胞瘤（HB）和肝细胞癌（HCC）。而一种名为复合型肝细胞胆管癌（Combined ...

Like many rare diseases, fibrolamellar hepatocellular carcinoma (FLC) mounts a ferocious attack against an unlucky few-in this case, children, adolescents, and young adults.

The targeting of telomeres offers promise for new cancer therapies, which can be aimed at disrupting the mechanisms that ...

Chlorcyclizine shows promise in reducing protoporphyrin-IX accumulation and liver damage in erythropoietic protoporphyria, ...

Immunotherapy is a modern approach to cancer treatment that uses a patient's own immune system to help fight tumors. It has ...

Two independent studies reveal that disease progression is delayed by combining two targeted therapies with the traditional ...

The number of people dying from liver cancer has nearly doubled in the past two decades and is projected to keep rising, new analysis shows, despite around half of cases being preventable.